Attached files

file filename
8-K - 8-K - BIO-TECHNE Corpk8earningsanddiv.txt
EX-99.1 - EARNINGS RELEASE Q2 - BIO-TECHNE Corpq2earningsrelease.txt

                  TECHNE CORPORATION DECLARES DIVIDEND


Minneapolis/February 4, 2014/ Techne Corporation (NASDAQ:TECH) announced that
its Board of Directors has decided to pay a dividend of $0.31 per share for
the quarter ended December 31, 2013.  The quarterly dividend will be payable
February 28, 2014 to all common shareholders of record on February 14, 2014.
Future cash dividends will be considered by the Board of Directors on a
quarterly basis.




*  *  *  *  *  *  *  *  *  *  *  *  *  *
Techne Corporation and Subsidiaries (the Company) are engaged in the
development, manufacture and sale of biotechnology products and clinical
diagnostic controls. These activities are conducted through the Company's two
operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems)
of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of
Abingdon, England.

R&D Systems is a specialty manufacturer of biological products. R&D Systems
has four subsidiaries: BiosPacific, Inc. (BiosPacific), located in
Emeryville, California, Boston Biochem, Inc., located in Cambridge,
Massachusetts, Bionostics Holdings Limited (Bionostics), operating in Devens,
Massachusetts, and R&D Systems China Co. Ltd., (R&D China), located in
Shanghai, China. BiosPacific is a worldwide supplier of biologics to
manufacturers of in vitro diagnostic systems and immunodiagnostic kits.
Boston Biochem is a leading developer and manufacturer of ubiquitin-related
research products.  Bionostics is a leading supplier of control solutions
used in point of care blood glucose and blood gas testing.

R&D China and R&D Europe distribute the Company's biotechnology products. R&D
Europe has two subsidiaries: Tocris Holdings Ltd. (Tocris) of Bristol,
England and R&D Systems GmbH, a German sales operation. Tocris is a leading
supplier of chemical reagents for non-clinical life science research.

Contact:  Chuck Kummeth, CEO
          (612) 379-8854